CRISPR Therapeutics public offering: the advisors

CRISPR Therapeutics, a Swiss gene editing company focused on developing transformative gene-based medicines, carried out an underwritten offering of 6,982,143 shares (including overallotment shares), resulting in gross proceeds of approximately USD 520 million. Goldman Sachs & Co. LLC, BofA Securities and Jefferies were acting as joint book-running managers for the offering. Canaccord Genuity, William Blair, SunTrust Robinson Humphrey and Roth Capital Partners were acting as co-managers for the offering. CRISPR is headquartered in Zug, Switzerland. CRISPR’s common shares are listed on Nasdaq.

The advisors 

Walder Wyss acted as Swiss counsel to CRISPR in connection with the transaction. The team was led by partner Alex Nikitine (Corporate/M&A, Capital Markets – pictured right) and managing associate Christian Lütolf (Corporate/M&A, Capital Markets) and further included managing associates Rafael Zemp (Corporate/M&A, Capital Markets), André Kuhn (Notary), trainee Jasmin Eicher (Capital Markets), partner Maurus Winzap (Tax) and counsel Janine Corti (Tax).

Homburger acted as legal counsel to Goldman Sachs & Co. LLC, BofA Securities, Inc. and Jefferies LLC as the joint book-running managers and representatives of the several underwriters in the offering. The team comprised partner Frank Gerhard (pictured left) and associate Lorenzo Togni (both Corporate/ M&A and Capital Markets).